DB:1E6

Stock Analysis Report

Executive Summary

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States.

Snowflake

Fundamentals

Outstanding track record with excellent balance sheet.


Similar Companies

Share Price & News

How has Eagle Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1E6 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

1000000

-1.6%

DE Biotechs

0.8%

DE Market


1 Year Return

24.7%

1000000

-8.9%

DE Biotechs

9.0%

DE Market

Return vs Industry: 1E6 exceeded the German Biotechs industry which returned -8.9% over the past year.

Return vs Market: 1E6 exceeded the German Market which returned 9% over the past year.


Shareholder returns

1000000IndustryMarket
7 Day0%-1.6%0.8%
30 Day2.8%-1.5%6.3%
90 Day10.1%-8.3%14.4%
1 Year24.7%24.7%-8.7%-8.9%12.4%9.0%
3 Year-27.4%-27.4%49.7%47.8%25.6%14.5%
5 Year469.9%469.9%-1.5%-4.6%41.0%21.8%

Price Volatility Vs. Market

How volatile is Eagle Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Eagle Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

42.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 1E6 (€56) is trading below our estimate of fair value (€96.48)

Significantly Below Fair Value: 1E6 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 1E6 is good value based on its PE Ratio (20.8x) compared to the Biotechs industry average (29.9x).

PE vs Market: 1E6 is poor value based on its PE Ratio (20.8x) compared to the German market (19.9x).


Price to Earnings Growth Ratio

PEG Ratio: 1E6 is poor value based on its PEG Ratio (3.4x)


Price to Book Ratio

PB vs Industry: 1E6 is overvalued based on its PB Ratio (4.9x) compared to the DE Biotechs industry average (3.1x).


Next Steps

Future Growth

How is Eagle Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

6.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1E6's forecast earnings growth (6.2% per year) is above the savings rate (0.2%).

Earnings vs Market: 1E6's earnings (6.2% per year) are forecast to grow slower than the German market (12.8% per year).

High Growth Earnings: 1E6's earnings are forecast to grow, but not significantly.

Revenue vs Market: 1E6's revenue (7.4% per year) is forecast to grow faster than the German market (4.9% per year).

High Growth Revenue: 1E6's revenue (7.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 1E6's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Eagle Pharmaceuticals performed over the past 5 years?

41.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1E6 has high quality earnings.

Growing Profit Margin: 1E6's current net profit margins (19.8%) are higher than last year (13.8%).


Past Earnings Growth Analysis

Earnings Trend: 1E6 has become profitable over the past 5 years, growing earnings by 41.7% per year.

Accelerating Growth: 1E6's earnings growth over the past year (42.1%) exceeds its 5-year average (41.7% per year).

Earnings vs Industry: 1E6 earnings growth over the past year (42.1%) exceeded the Biotechs industry 5.4%.


Return on Equity

High ROE: 1E6's Return on Equity (24.5%) is considered high.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Eagle Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: 1E6's short term assets ($185.7M) exceeds its short term liabilities ($51.7M)

Long Term Liabilities: 1E6's short term assets (185.7M) exceeds its long term liabilities (37.4M)


Debt to Equity History and Analysis

Debt Level: 1E6's debt to equity ratio (23.7%) is considered satisfactory

Reducing Debt: Insufficient data to determine if 1E6's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: 1E6's debt is well covered by operating cash flow (221.3%).

Interest Coverage: 1E6's interest payments on its debt are well covered by EBIT (38.7x coverage).


Balance Sheet

Inventory Level: 1E6 has a low level of unsold assets or inventory.

Debt Coverage by Assets: 1E6's debt is covered by short term assets (assets are 4.5x debt).


Next Steps

Dividend

What is Eagle Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.6%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 1E6's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 1E6's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1E6's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1E6's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1E6's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Eagle Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

2.7yrs

Average management tenure


CEO

Scott Tarriff (59yo)

12.8yrs

Tenure

US$11,324,456

Compensation

Mr. Scott L. Tarriff founded Eagle Pharmaceuticals Inc. in January 2007 and has been its Chief Executive Officer since January 2007. Mr. Tarriff served as the Chief Executive Officer and President at Par P ...


CEO Compensation Analysis

Compensation vs Market: Scott's total compensation ($USD11.32M) is above average for companies of similar size in the German market ($USD1.15M).

Compensation vs Earnings: Scott's compensation has increased by more than 20% in the past year.


Management Age and Tenure

2.7yrs

Average Tenure

58yo

Average Age

Experienced Management: 1E6's management team is considered experienced (2.7 years average tenure).


Board Age and Tenure

3.3yrs

Average Tenure

58yo

Average Age

Experienced Board: 1E6's board of directors are considered experienced (3.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$8,046,39313 May 19
Hudson Executive Capital LP
EntityCompany
Shares159,223
Max PriceUS$51.55

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Scott Tarriff (59yo)

    CEO & Director

    • Tenure: 12.8yrs
    • Compensation: US$11.32m
  • Pete Meyers (49yo)

    Chief Financial Officer

    • Tenure: 2.5yrs
    • Compensation: US$2.67m
  • David Pernock (66yo)

    President & COO

    • Tenure: 2.8yrs
    • Compensation: US$3.68m
  • Adrian Hepner (58yo)

    Executive VP & Chief Medical Officer

    • Tenure: 4.8yrs
    • Compensation: US$3.13m
  • Dan O'Connor (39yo)

    Chief Strategy Officer of Biologics & Corporate Development

    • Tenure: 2.5yrs
  • Mike Moran

    Executive VP & Head of Sales

    • Tenure: 0.8yrs
  • Reiner Nowak

    Executive

    • Tenure: 0yrs
    • Compensation: US$12.45k

Board Members

  • Steven Ratoff (76yo)

    Independent Director

    • Tenure: 12.7yrs
    • Compensation: US$334.78k
  • Scott Tarriff (59yo)

    CEO & Director

    • Tenure: 12.8yrs
    • Compensation: US$11.32m
  • Richard Edlin (57yo)

    Independent Director

    • Tenure: 2.7yrs
    • Compensation: US$318.53k
  • Doug Braunstein (58yo)

    Independent Director

    • Tenure: 3.3yrs
    • Compensation: US$319.78k
  • Robert Glenning (58yo)

    Independent Director

    • Tenure: 3.3yrs
    • Compensation: US$328.53k
  • Mike Graves (56yo)

    Chairman

    • Tenure: 3.3yrs
    • Compensation: US$392.28k
  • Jennifer Simpson

    Director

    • Tenure: 0.3yrs

Company Information

Eagle Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Eagle Pharmaceuticals, Inc.
  • Ticker: 1000000
  • Exchange: DB
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$844.750m
  • Listing Market Cap: US$767.033m
  • Shares outstanding: 13.67m
  • Website: https://www.eagleus.com

Number of Employees


Location

  • Eagle Pharmaceuticals, Inc.
  • 50 Tice Boulevard
  • Suite 315
  • Woodcliff Lake
  • New Jersey
  • 7677
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EGRXNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDFeb 2014
1000000DB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2014

Biography

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The co ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/12 21:39
End of Day Share Price2019/11/12 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.